CompletedNot Applicable

Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

United States8 participantsStarted 2018-11-28

Plain-language summary

This trial studies how well dynamic susceptibility contrast-magnetic resonance imaging (MRI) works in determining radiation necrosis and tumor progression in participants with cancer that has spread to the brain and are being treated with radiation therapy. Diagnostic procedures, such as dynamic susceptibility contrast-MRI, may improve the ability to determine indeterminate post-treatment changes seen on imaging after radiation therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically proven diagnosis of invasive malignancy with at least radiographic evidence of intracranial disease as seen on MRI. * At least one identifiable intracranial lesion ≥ 1 cm in diameter enrolled within 4 weeks of diagnosis. * Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2. Exclusion Criteria: * Planned whole-brain radiotherapy (WBRT) with boost. * Leptomeningeal disease. * Inadequate renal function (estimated glomerular filtration rate \[eGFR\] \> 30 ml/min/1.73 m²) or contrast allergy. * Non-MRI compatible pacemaker with pacemaker dependence.

What they're measuring

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative cerebral blood volume (rCBV)

Timeframe: Baseline up to 1 year

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative peak height (rPH)

Timeframe: Baseline up to 1 year

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: percentage of signal intensity recovery (PSR)

Timeframe: Baseline up to 1 year

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: mean transit time (MTT)

Timeframe: Baseline up to 1 year

Trial details

NCT IDNCT03680144

SponsorEmory University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-05

View on ClinicalTrials.gov More Invasive Malignant Neoplasm trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative cerebral blood volume (rCBV)

Timeframe: Baseline up to 1 year

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: relative peak height (rPH)

Timeframe: Baseline up to 1 year

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: percentage of signal intensity recovery (PSR)

Timeframe: Baseline up to 1 year

Change in dynamic susceptibility contrast (DSC)-magnetic resonance imaging (MRI) parameters: mean transit time (MTT)

Timeframe: Baseline up to 1 year